The DOI matches its Crossref record; 1,264 of the 1,264 references it cites were found in a registry or an index.
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Open accessAbstract
Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 601–800 of 1,264
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240
Sen, R., & Baltimore, D. (2006) · PubMed · Cited by 239
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar, J., Gast, K., Quiroga, D., Lustberg, M., & Williams, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840984 · Cited by 239
Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters
Ciscato, F., Ferrone, L., Masgras, I., Laquatra, C., & Rasola, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094716 · Cited by 239
PDGF receptor signaling networks in normal and cancer cells
Demoulin, J.-B., & Essaghir, A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.03.003 · Cited by 238
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
Cancer epigenetics in clinical practice
Davalos, V., & Esteller, M. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21765 · Cited by 237
Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., Huang, A., Yang, N.-Y., Nishimura, M., Greve, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302725110 · Cited by 236
Self-citationExosomes in gastric cancer: roles, mechanisms, and applications
Fu, M., Gu, J., Jiang, P., Qian, H., Xu, W., & Zhang, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1001-7 · Cited by 236
The Warburg effect: a signature of mitochondrial overload
Wang, Y., & Patti, G. J. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.03.013 · Cited by 235
Posch, C., Moslehi, H., Feeney, L., Green, G. A., Ebaee, A., Feichtenschlager, V., Chong, K., Peng, L., Dimon, M. T., Phillips, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216013110 · Cited by 234
Transient SNAIL1 Expression Is Necessary for Metastatic Competence in Breast Cancer
Tran, H. D., Luitel, K., Kim, M., Zhang, K., Longmore, G. D., & Tran, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0923 · Cited by 233
Autophagic Regulation of p62 is Critical for Cancer Therapy
Islam, M. A., Sooro, M. A., & Zhang, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051405 · Cited by 233
Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review
Zou, X., Tang, X.-Y., Qu, Z.-Y., Sun, Z.-W., Ji, C.-F., Li, Y.-J., & Guo, S.-D. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.113 · Cited by 232
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01170 · Cited by 231
Leenders, W. P. J., Küsters, B., Verrijp, K., Maass, C., Wesseling, P., Heerschap, A., Ruiter, D., Ryan, A., & de Waal, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0823 · Cited by 231
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Self-citationAddie, M., Ballard, P., Buttar, D., Crafter, C., Currie, G., Davies, B. R., Debreczeni, J., Dry, H., Dudley, P., Greenwood, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301762v · Cited by 230
Wild-derived inbred mouse strains have short telomeres
Hemann, M. T. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.22.4474 · Cited by 228
Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms
Ferreira, P. M. P., Sousa, R. W. R. D., Ferreira, J. R. D. O., Militão, G. C. G., & Bezerra, D. P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105582 · Cited by 227
Lymphatic endothelium: a new frontier of metastasis research
Karkkainen, M. J., Mäkinen, T., & Alitalo, K. (2002) · Nature Cell Biology · doi:10.1038/ncb0102-e2 · Cited by 226
Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future
Van Poppel, H., Albreht, T., Basu, P., Hogenhout, R., Collen, S., & Roobol, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00638-6 · Cited by 226
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
on behalf of the MErCuRIC consortium, Bradley, C. A., Salto-Tellez, M., Laurent-Puig, P., Bardelli, A., Rolfo, C., Tabernero, J., Khawaja, H. A., Lawler, M., Johnston, P. G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.40 · Cited by 225
Challenges of Cancer Biomarker Profiling
Bensalah, K., Montorsi, F., & Shariat, S. F. (2007) · European Urology · doi:10.1016/j.eururo.2007.09.036 · Cited by 224
IDH Mutation in Glioma: New Insights and Promises for the Future
Turkalp, Z., Karamchandani, J., & Das, S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1205 · Cited by 224
Marian, C. O., Cho, S. K., Mcellin, B. M., Maher, E. A., Hatanpaa, K. J., Madden, C. J., Mickey, B. E., Wright, W. E., Shay, J. W., & Bachoo, R. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2850 · Cited by 224
Circulating tumor DNA: current challenges for clinical utility
Dang, D. K., & Park, B. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154941 · Cited by 224
Ferritin is secreted via 2 distinct nonclassical vesicular pathways
Truman-Rosentsvit, M., Berenbaum, D., Spektor, L., Cohen, L. A., Belizowsky-Moshe, S., Lifshitz, L., Ma, J., Li, W., Kesselman, E., Abutbul-Ionita, I., et al. (2018) · Blood · doi:10.1182/blood-2017-02-768580 · Cited by 223
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
Treatment of Helicobacter pylori infection: Current status and future concepts
Yang, J.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5283 · Cited by 222
Sfanos, K. S., Sauvageot, J., Fedor, H. L., Dick, J. D., De Marzo, A. M., & Isaacs, W. B. (2008) · The Prostate · doi:10.1002/pros.20680 · Cited by 219
Hulit, J., Suyama, K., Chung, S., Keren, R., Agiostratidou, G., Shan, W., Dong, X., Williams, T. M., Lisanti, M. P., Knudsen, K., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3401 · Cited by 218
Circulating Tumor Cell Isolation and Diagnostics: Toward Routine Clinical Use
van de Stolpe, A., Pantel, K., Sleijfer, S., Terstappen, L. W., & den Toonder, J. M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1254 · Cited by 218
Killing cancer cells by flipping the Bcl-2/Bax switch
Cory, S., & Adams, J. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.012 · Cited by 217
HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor
Date, K., Matsumoto, K., Shimura, H., Tanaka, M., & Nakamura, T. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01475-0 · Cited by 217
Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma
Talvensaari-Mattila, A., P��kk�, P., H�yhty�, M., Blanco-Sequeiros, G., & Turpeenniemi-Hujanen, T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1153::aid-cncr14>3.0.co;2-4 · Cited by 217
Antiangiogenic Therapy for Cancer: An Update
Al‐Husein, B., Abdalla, M., Trepte, M., DeRemer, D. L., & Somanath, P. R. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1147 · Cited by 216
Vaswani, R. G., Gehling, V. S., Dakin, L. A., Cook, A. S., Nasveschuk, C. G., Duplessis, M., Iyer, P., Balasubramanian, S., Zhao, F., Good, A. C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01315 · Cited by 216
Self-citationLazzeri, M., Haese, A., de la Taille, A., Palou Redorta, J., McNicholas, T., Lughezzani, G., Scattoni, V., Bini, V., Freschi, M., Sussman, A., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.01.011 · Cited by 215
BECLIN1: Protein Structure, Function and Regulation
Tran, S., Fairlie, W. D., & Lee, E. F. (2021) · Cells · doi:10.3390/cells10061522 · Cited by 215
Tian, M., Cui, Y.-Z., Song, G.-H., Zong, M.-J., Zhou, X.-Y., Chen, Y., & Han, J.-X. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-241 · Cited by 214
Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis.
Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Núñez, G., & Castle, V. P. (1995) · PubMed · Cited by 214
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse
TRACERx Consortium, Chemi, F., Rothwell, D. G., McGranahan, N., Gulati, S., Abbosh, C., Pearce, S. P., Zhou, C., Wilson, G. A., Jamal-Hanjani, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0593-1 · Cited by 213
Angiogenic inhibitors: a new therapeutic strategy in oncology
Gasparini, G., Longo, R., Toi, M., & Ferrara, N. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0342 · Cited by 212
Bryant, H. E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl108 · Cited by 212
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer
Nunnery, S. E., & Mayer, I. A. (2020) · Drugs · doi:10.1007/s40265-020-01394-w · Cited by 212
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies
Gao, J., & Pickett, H. A. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00490-1 · Cited by 212
Basit, F., Cristofanon, S., & Fulda, S. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.45 · Cited by 211
Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01665 · Cited by 211
Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis
Lee, S. H., Jeong, D., Han, Y.-S., & Baek, M. J. (2015) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2015.89.1.1 · Cited by 210
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
Zambrano, A., Molt, M., Uribe, E., & Salas, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133374 · Cited by 210
Synthetic biomarkers: a twenty-first century path to early cancer detection
Kwong, G. A., Ghosh, S., Gamboa, L., Patriotis, C., Srivastava, S., & Bhatia, S. N. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00389-3 · Cited by 209
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02903 · Cited by 208
Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
Tao, J., Bauer, D. E., & Chiarle, R. (2023) · Nature Communications · doi:10.1038/s41467-023-35886-6 · Cited by 207
SASP: Tumor Suppressor or Promoter? Yes!
Rao, S. G., & Jackson, J. G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.001 · Cited by 206
A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells
Wakita, M., Takahashi, A., Sano, O., Loo, T. M., Imai, Y., Narukawa, M., Iwata, H., Matsudaira, T., Kawamoto, S., Ohtani, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15719-6 · Cited by 206
Fluorescent excitation transfer immunoassay. A general method for determination of antigens.
Ullman, E. F., Schwarzberg, M., & Rubenstein, K. E. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33277-5 · Cited by 206
Wengner, A. M., Siemeister, G., Lücking, U., Lefranc, J., Wortmann, L., Lienau, P., Bader, B., Bömer, U., Moosmayer, D., Eberspächer, U., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0019 · Cited by 206
Wang, J., Ye, C., Chen, C., Xiong, H., Xie, B., Zhou, J., Chen, Y., Zheng, S., & Wang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.15171 · Cited by 205
Cremona, C. A., & Behrens, A. (2014) · Oncogene · doi:10.1038/onc.2013.275 · Cited by 204
Accumulation of p62/SQSTM 1 is associated with poor prognosis in patients with lung adenocarcinoma
Inoue, D., Suzuki, T., Mitsuishi, Y., Miki, Y., Suzuki, S., Sugawara, S., Watanabe, M., Sakurada, A., Endo, C., Uruno, A., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02216.x · Cited by 204
GLUT1 as a therapeutic target in hepatocellular carcinoma
Amann, T., & Hellerbrand, C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903307509 · Cited by 204
Banerjee, S., Tian, T., Wei, Z., Shih, N., Feldman, M. D., Alwine, J. C., Coukos, G., & Robertson, E. S. (2017) · Oncotarget · doi:10.18632/oncotarget.16717 · Cited by 204
KRAS4A directly regulates hexokinase 1
Amendola, C. R., Mahaffey, J. P., Parker, S. J., Ahearn, I. M., Chen, W.-C., Zhou, M., Court, H., Shi, J., Mendoza, S. L., Morten, M. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1832-9 · Cited by 203
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203
Epithelial (E‐) and placentae (P‐) cadherin cell adhesion molecule expression in breast carcinoma
Rasbridge, S. A., Gillett, C. E., Sampson, S. A., Walsh, F. S., & Millis, R. R. (1993) · The Journal of Pathology · doi:10.1002/path.1711690211 · Cited by 201
William, A. D., Lee, A. C.-H., Blanchard, S., Poulsen, A., Teo, E. L., Nagaraj, H., Tan, E., Chen, D., Williams, M., Sun, E. T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200326p · Cited by 201
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s189391 · Cited by 200
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Beclin-1: Autophagic regulator and therapeutic target in cancer
Fu, L.-L., Cheng, Y., & Liu, B. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.02.007 · Cited by 199
Höckendorf, U., Yabal, M., Herold, T., Munkhbaatar, E., Rott, S., Jilg, S., Kauschinger, J., Magnani, G., Reisinger, F., Heuser, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.002 · Cited by 199
BCL2 and MCL1 inhibitors for hematologic malignancies
Roberts, A. W., Wei, A. H., & Huang, D. C. S. (2021) · Blood · doi:10.1182/blood.2020006785 · Cited by 199
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
Roskoski Jr., R. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106037 · Cited by 198
Zhao, S., Ma, D., Xiao, Y., Li, X.-M., Ma, J.-L., Zhang, H., Xu, X.-L., Lv, H., Jiang, W.-H., Yang, W.-T., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0982 · Cited by 197
Research progress of mTOR inhibitors
Chen, Y., & Zhou, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112820 · Cited by 197
The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?
Hu, X., Chen, R., Wei, Q., & Xu, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.64537 · Cited by 197
Breast-cancer screening with mammography in women aged 40–49 years
Organizing Committee and Collaborators, F. M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961211)68:6<727::aid-ijc6>3.0.co;2-5 · Cited by 196
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17778 · Cited by 196
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
Sethi, S. N., Macoska, J. A., Chen, W., & Sarkar, F. H. (2010) · PubMed · Cited by 195
Scotto Rosato, A., Montefusco, S., Soldati, C., Di Paola, S., Capuozzo, A., Monfregola, J., Polishchuk, E., Amabile, A., Grimm, C., Lombardo, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13572-w · Cited by 195
Targeting apoptosis pathways by Celecoxib in cancer
Jendrossek, V. (2013) · Cancer Letters · doi:10.1016/j.canlet.2011.01.012 · Cited by 194
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Cheng, M. L., Pectasides, E., Hanna, G. J., Parsons, H. A., Choudhury, A. D., & Oxnard, G. R. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21650 · Cited by 193
MMP-9 expression varies according to molecular subtypes of breast cancer
Yousef, E. M., Tahir, M. R., St-Pierre, Y., & Gaboury, L. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-609 · Cited by 192
Sausville, E., LoRusso, P., Carducci, M., Carter, J., Quinn, M. F., Malburg, L., Azad, N., Cosgrove, D., Knight, R., Barker, P., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2380-5 · Cited by 192
Molecular Insight of Regorafenib Treatment for Colorectal Cancer
Arai, H., Battaglin, F., Wang, J., Lo, J. H., Soni, S., Zhang, W., & Lenz, H.-J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101912 · Cited by 191
Ju, H.-Q., Lu, Y.-X., Chen, D.-L., Zuo, Z.-X., Liu, Z.-X., Wu, Q.-N., Mo, H.-Y., Wang, Z.-X., Wang, D.-S., Pu, H.-Y., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy160 · Cited by 191
Will mTOR inhibitors make it as cancer drugs?
Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00275-7 · Cited by 190
Pellini, B., & Chaudhuri, A. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01929 · Cited by 190
Clinical application and detection techniques of liquid biopsy in gastric cancer
Ma, S., Zhou, M., Xu, Y., Gu, X., Zou, M., Abudushalamu, G., Yao, Y., Fan, X., & Wu, G. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01715-z · Cited by 190
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
King, C., Diaz, H. B., McNeely, S., Barnard, D., Dempsey, J., Blosser, W., Beckmann, R., Barda, D., & Marshall, M. S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1037 · Cited by 187
A new wave of innovations within the DNA damage response
Li, Q., Qian, W., Zhang, Y., Hu, L., Chen, S., & Xia, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01548-8 · Cited by 187
Self-citationMolecular characterization of breast cancer CTCs associated with brain metastasis
Boral, D., Vishnoi, M., Liu, H. N., Yin, W., Sprouse, M. L., Scamardo, A., Hong, D. S., Tan, T. Z., Thiery, J. P., Chang, J. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00196-1 · Cited by 186
The Biochemical and Clinical Perspectives of Lactate Dehydrogenase: An Enzyme of Active Metabolism
Khan, A. A., Allemailem, K. S., Alhumaydhi, F. A., Gowder, S. J. T., & Rahmani, A. H. (2020) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666191230141110 · Cited by 186
Developing dietary interventions as therapy for cancer
Taylor, S. R., Falcone, J. N., Cantley, L. C., & Goncalves, M. D. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00485-y · Cited by 185
Mechanisms of FGFR-mediated carcinogenesis
Ahmad, I., Iwata, T., & Leung, H. Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.004 · Cited by 184
Advances in antibody-based therapy in oncology
Zinn, S., Vazquez-Lombardi, R., Zimmermann, C., Sapra, P., Jermutus, L., & Christ, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00516-z · Cited by 184
Biofilm Producing Salmonella Typhi: Chronic Colonization and Development of Gallbladder Cancer
Di Domenico, E. G., Cavallo, I., Pontone, M., Toma, L., & Ensoli, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091887 · Cited by 183
Tumor markers in clinical practice: General principles and guidelines
Sharma, S. (2009) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.56328 · Cited by 181
The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis
Fu, Z., Deng, B., Liao, Y., Shan, L., Yin, F., Wang, Z., Zeng, H., Zuo, D., Hua, Y., & Cai, Z. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-580 · Cited by 180
The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction
Li, S., Yi, M., Dong, B., Tan, X., Luo, S., & Wu, K. (2021) · International Journal of Cancer · doi:10.1002/ijc.33386 · Cited by 180
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
Regulation of Autophagy By Signaling Through the Atg1/ULK1 Complex
Papinski, D., & Kraft, C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.03.030 · Cited by 179
Kristeleit, R. S., Lisyanskaya, A., Fedenko, A., Dvorkin, M., de Melo, A. C., Shparyk, Y. V., Rakhmatullina, I., Bondarenko, I., Colombo, N., Svintsitskiy, V., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00122-x · Cited by 179
Blum, R., Jacob‐Hirsch, J., Amariglio, N., Rechavi, G., & Kloog, Y. (2005) · PubMed · Cited by 178
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
Durazo, F. A., Blatt, L. M., Corey, W. G., Lin, J., Han, S., Saab, S., Busuttil, R. W., & Tong, M. J. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05395.x · Cited by 177
An allosteric mechanism for potent inhibition of human ATP-citrate lyase
Wei, J., Leit, S., Kuai, J., Therrien, E., Rafi, S., Harwood, H. J., DeLaBarre, B., & Tong, L. (2019) · Nature · doi:10.1038/s41586-019-1094-6 · Cited by 176
Telomerase as a universal tumor-associated antigen for cancer immunotherapy
Vonderheide, R. H. (2002) · Oncogene · doi:10.1038/sj.onc.1205074 · Cited by 175
Kannagi, R. (2007) · PubMed · Cited by 175
Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
Lakemeyer, L., Sander, S., Wittau, M., Henne-Bruns, D., Kornmann, M., & Lemke, J. (2021) · Diseases · doi:10.3390/diseases9010021 · Cited by 175
Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies
Yao, C., Wu, S., Kong, J., Sun, Y., Bai, Y., Zhu, R., Li, Z., Sun, W., & Zheng, L. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0449 · Cited by 175
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Corona, S. P., & Generali, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s137783 · Cited by 174
Mei, Z., Addo, O. Y., Jefferds, M. E., Sharma, A. J., Flores‐Ayala, R. C., & Brittenham, G. M. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00168-x · Cited by 174
Soria, J.-C., DeBraud, F., Bahleda, R., Adamo, B., Andre, F., Dientsmann, R., Delmonte, A., Cereda, R., Isaacson, J., Litten, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu390 · Cited by 173
MLKL: Functions beyond serving as the Executioner of Necroptosis
Zhan, C., Huang, M., Yang, X., & Hou, J. L. (2021) · Theranostics · doi:10.7150/thno.54072 · Cited by 173
Self-citationSchaeffer, E. M., Marchionni, L., Huang, Z., Simons, B., Blackman, A., Yu, W., Parmigiani, G., & Berman, D. M. (2008) · Oncogene · doi:10.1038/onc.2008.327 · Cited by 172
Chen, J., Jin, S. S., Abraham, V., Huang, X., Liu, B. A., Mitten, M. J., Nimmer, P. M., Lin, X., Smith, M. L., Shen, Y., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0415 · Cited by 172
Varghese, S., Pramanik, S., Williams, L. J., Hodges, H. R., Hudgens, C. W., Fischer, G. M., Luo, C. K., Knighton, B., Tan, L., Lorenzi, P. L., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0430 · Cited by 171
Finn, R. S., Boer, K., Bondarenko, I., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y. V., Thummala, A., Voitko, N., Bananis, E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05755-7 · Cited by 171
Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
Leshchiner, E. S., Parkhitko, A. A., Bird, G. H., Luccarelli, J., Bellairs, J. A., Escudero, S., Opoku-Nsiah, K., Godes, M., Perrimon, N., & Walensky, L. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413185112 · Cited by 170
Schmitz, K. J., Ademi, C., Bertram, S., Schmid, K. W., & Baba, H. A. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0946-x · Cited by 170
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.021 · Cited by 170
Kwak, E. L., Ahronian, L. G., Siravegna, G., Mussolin, B., Borger, D. R., Godfrey, J. T., Jessop, N. A., Clark, J. W., Blaszkowsky, L. S., Ryan, D. P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0748 · Cited by 169
Absence of RIPK3 predicts necroptosis resistance in malignant melanoma
Geserick, P., Wang, J., Schilling, R., Horn, S., Harris, P. A., Bertin, J., Gough, P. J., Feoktistova, M., & Leverkus, M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.240 · Cited by 169
FENG, X., SONG, Q., YU, A., TANG, H., PENG, Z., & WANG, X. (2015) · Neoplasma · doi:10.4149/neo_2015_071 · Cited by 168
Autophagy: A Druggable Process
Morel, E., Mehrpour, M., Botti, J., Dupont, N., Hamaï, A., Nascimbeni, A. C., & Codogno, P. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104936 · Cited by 168
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167
NK4 (HGF‐antagonist/angiogenesis inhibitor) in cancer biology and therapeutics
Matsumoto, K., & Nakamura, T. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01440.x · Cited by 166
Acute Pancreatitis Secondary to Pancreatic Carcinoma
Mujica, V. R., Barkin, J. S., & Go, V. L. W. (2000) · Pancreas · doi:10.1097/00006676-200011000-00001 · Cited by 166
KSR stimulates Raf-1 activity in a kinase-independent manner
Michaud, N. R., Therrien, M., Cacace, A., Edsall, L. C., Spiegel, S., Rubin, G. M., & Morrison, D. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.12792 · Cited by 166
Sartor, O., Coleman, R. E., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Vogelzang, N. J., Bruland, Ø., Kobina, S., Wilhelm, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx044 · Cited by 166
Recent advances in the discovery of small molecule c-Met Kinase inhibitors
Parikh, P. K., & Ghate, M. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.044 · Cited by 166
André, T., Berton, D., Curigliano, G., Sabatier, R., Tinker, A. V., Oaknin, A., Ellard, S. L., de Braud, F., Arkenau, H., Trigo, J. M., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.41165 · Cited by 166
Park, J. M., Huang, S., Wu, T., Foster, N. R., & Sinicrope, F. A. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.22954 · Cited by 165
Palbociclib: First Global Approval
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0379-9 · Cited by 165
Birrer, M., Johnson, M. E., Hao, K., Wong, K. K., Park, D., Bell, A., Welch, W., Berkowitz, R., & Mok, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0795 · Cited by 165
Potential therapeutic targets of epithelial–mesenchymal transition in melanoma
Pearlman, R. L., Montes de Oca, M. K., Pal, H. C., & Afaq, F. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.029 · Cited by 165
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Yoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.038 · Cited by 164
Petrelli, A., Circosta, P., Granziero, L., Mazzone, M., Pisacane, A., Fenoglio, S., Comoglio, P. M., & Giordano, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508156103 · Cited by 164
Li, X., He, L., Che, K. H., Funderburk, S. F., Pan, L., Pan, N., Zhang, M., Yue, Z., & Zhao, Y. (2012) · Nature Communications · doi:10.1038/ncomms1648 · Cited by 164
Self-citationE-cadherin: a differentiation marker in thyroid malignancies.
Brabant, G. E., Hoang‐Vu, C., Cetin, Y., Dralle, H., Scheumann, G. F. W., Mölne, J., Hansson, G. K., Jansson, S., Ericson, L. E., & Nilsson, M. (1993) · PubMed · Cited by 164
Richards, C. H., Mohammed, Z., Qayyum, T., Horgan, P. G., & McMillan, D. C. (2011) · Future Oncology · doi:10.2217/fon.11.99 · Cited by 164
PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
Bazzichetto, C., Conciatori, F., Pallocca, M., Falcone, I., Fanciulli, M., Cognetti, F., Milella, M., & Ciuffreda, L. (2019) · Cancers · doi:10.3390/cancers11040435 · Cited by 164
Neddylation of PTEN regulates its nuclear import and promotes tumor development
Xie, P., Peng, Z., Chen, Y., Li, H., Du, M., Tan, Y., Zhang, X., Lu, Z., Cui, C.-P., Liu, C. H., et al. (2021) · Cell Research · doi:10.1038/s41422-020-00443-z · Cited by 164
Tumor Markers in Detection of Lung Cancer
(2006) · Advances in Clinical Chemistry · doi:10.1016/s0065-2423(06)42001-1 · Cited by 163
Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia
Reyna, D. E., Garner, T. P., Lopez, A., Kopp, F., Choudhary, G. S., Sridharan, A., Narayanagari, S.-R., Mitchell, K., Dong, B., Bartholdy, B. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.001 · Cited by 163
A method for measuring the distribution of the shortest telomeres in cells and tissues
Lai, T.-P., Zhang, N., Noh, J., Mender, I., Tedone, E., Huang, E., Wright, W. E., Danuser, G., & Shay, J. W. (2017) · Nature Communications · doi:10.1038/s41467-017-01291-z · Cited by 163
Moschos, S. J., Sullivan, R. J., Hwu, W., Ramanathan, R. K., Adjei, A. A., Fong, P. C. C., Shapira‐Frommer, R., Tawbi, H. A.-H., Rubino, J., Rush, T. S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.92352 · Cited by 163
Riches, L. C., Trinidad, A. G., Hughes, G., Jones, G. N., Hughes, A. M., Thomason, A. G., Gavine, P., Cui, A., Ling, S., Stott, J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1394 · Cited by 163
The Role of Exosomes and Their Applications in Cancer
Zhou, Y., Zhang, Y., Gong, H., Luo, S., & Cui, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212204 · Cited by 163
Self-citationBocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M. L., du Manoir, J. M., Weinerman, A., Emmenegger, U., Ma, L., Thorpe, P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0401 · Cited by 162
Thelin, E. P., Jeppsson, E., Frostell, A., Svensson, M., Mondello, S., Bellander, B.-M., & Nelson, D. W. (2016) · Critical Care · doi:10.1186/s13054-016-1450-y · Cited by 162
Exosomes as a liquid biopsy for lung cancer
Cui, S., Cheng, Z., Qin, W., & Jiang, L. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.012 · Cited by 162
Harding, J. J., Moreno, V., Bang, Y.-J., Hong, M. H., Patnaik, A., Trigo, J., Szpurka, A. M., Yamamoto, N., Doi, T., Fu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4405 · Cited by 161
Macaulay, V. M., O'Byrne, K. J., Saunders, M. P., et al. (1999) · PubMed · Cited by 161
FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer
Nomura, S., Yoshitomi, H., Takano, S., Shida, T., Kobayashi, S., Ohtsuka, M., Kimura, F., Shimizu, H., Yoshidome, H., Kato, A., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604473 · Cited by 161
Blum, R., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., & Kloog, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.999.65.3 · Cited by 161
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Riely, G. J., Johnson, M. L., Medina, C., Rizvi, N. A., Miller, V. A., Kris, M. G., Pietanza, M. C., Azzoli, C. G., Krug, L. M., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318223c099 · Cited by 160
Identification of pyrazolopyridazinones as PDEδ inhibitors
Papke, B., Murarka, S., Vogel, H. A., Martín-Gago, P., Kovacevic, M., Truxius, D. C., Fansa, E. K., Ismail, S., Zimmermann, G., Heinelt, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11360 · Cited by 160
The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
Wang, H., Rao, B., Lou, J., Li, J., Liu, Z., Li, A., Cui, G., Ren, Z., & Yu, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00055 · Cited by 160
Haria, M., Bryson, H. M., & Goa, K. L. (1996) · Drugs · doi:10.2165/00003495-199651040-00006 · Cited by 159
Erdafitinib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01142-9 · Cited by 159
Kantarjian, H. M., Roboz, G. J., Kropf, P. L., Yee, K. W. L., O'Connell, C. L., Tibes, R., Walsh, K. J., Podoltsev, N. A., Griffiths, E. A., Jabbour, E., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30576-4 · Cited by 158
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
Wedam, S., Fashoyin-Aje, L., Bloomquist, E., Tang, S., Sridhara, R., Goldberg, K. B., Theoret, M. R., Amiri-Kordestani, L., Pazdur, R., & Beaver, J. A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2580 · Cited by 158
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers
Comandatore, A., Frańczak, M., Smolenski, R. T., Morelli, L., Peters, G. J., & Giovannetti, E. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.001 · Cited by 158
Li, N., Babaei‐Jadidi, R., Lorenzi, F., Spencer‐Dene, B., Clarke, P. A., Domingo, E., Tulchinsky, E. M., Vries, R. G. J., Kerr, D. J., Pan, Y., et al. (2019) · Oncogenesis · doi:10.1038/s41389-019-0125-3 · Cited by 157
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Adamaki, M., & Zoumpourlis, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107932 · Cited by 157
Huang, Y., Fan, X.-G., Wang, Z.-M., Zhou, J.-H., Tian, X.-F., & Li, N. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.018556 · Cited by 156
Self-citationIsaacson, K. J., Jensen, M. M., Subrahmanyam, N. B., & Ghandehari, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.034 · Cited by 156
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Akhave, N. S., Biter, A. B., & Hong, D. S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1616 · Cited by 156
Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors
Olszewska, N., Kowalewski, J., & Lewandowska, M. A. (2020) · Molecules · doi:10.3390/molecules25081864 · Cited by 155
Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response
Ashrafizadeh, M., Paskeh, M. D. A., Mirzaei, S., Gholami, M. H., Zarrabi, A., Hashemi, F., Hushmandi, K., Hashemi, M., Nabavi, N., Crea, F., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02293-6 · Cited by 155
Joseph, I., Tressler, R., Bassett, E., Harley, C. B., Buseman, C. M., Pattamatta, P., Wright, W. E., Shay, J. W., & Go, N. F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0233 · Cited by 154
Recipient factors in faecal microbiota transplantation: one stool does not fit all
Danne, C., Rolhion, N., & Sokol, H. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00441-5 · Cited by 154
Performance assessment of DNA sequencing platforms in the ABRF Next-Generation Sequencing Study
Foox, J., Tighe, S. W., Nicolet, C. M., Zook, J. M., Byrska‐Bishop, M. S., Clarke, W. E., Khayat, M. M., Mahmoud, M., Laaguiby, P. K., Herbert, Z. T., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01049-5 · Cited by 154
Self-citationZauderer, M. G., Szlosarek, P. W., Moulec, S. L., Popat, S., Taylor, P., Planchard, D., Scherpereel, A., Koczywas, M., Forster, M. D., Cameron, R. B., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00277-7 · Cited by 154
Rudek, M. A., Figg, W. D., Dyer, V., Dahut, W. L., Turner, M. L. C., Steinberg, S. M., Liewehr, D. J., Köhler, D., Pluda, J. M., & Reed, E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.584 · Cited by 153
Clinical biochemistry of neuron specific enolase
Kaiser, E., Kuzmits, R., Pregant, P., Burghuber, O. C., & Worofka, W. (1989) · Clinica Chimica Acta · doi:10.1016/0009-8981(89)90268-4 · Cited by 152
Hirte, H. W., Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B. E., Tu, D., Sadura, A., Brundage, M., & Seymour, L. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.020 · Cited by 152
The Role of PDGFs and PDGFRs in Colorectal Cancer
Manzat-Saplacan, R. M., Bălăcescu, L., Gherman, C. D., Chira, R. I., Anca, C., Mircea, P. A., Lisencu, C. I., & Bălăcescu, O. (2017) · Mediators of Inflammation · doi:10.1155/2017/4708076 · Cited by 151
The Role of CDK4/6 Inhibition in Breast Cancer
Murphy, C. G., & Dickler, M. N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0443 · Cited by 150
Boyd, M. R., Farina, C., Belfiore, P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., & Bowman, E. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29517-3 · Cited by 150
Lesina, M., Wörmann, S. M., Morton, J. P., Diakopoulos, K. N., Korneeva, O., Wimmer, M., Einwächter, H., Sperveslage, J., Demir, İ. E., Kehl, T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86477 · Cited by 149
Mateo, J., Ganji, G., Lemech, C., Burris, H. A., Han, S., Swales, K. E., Decordova, S., DeYoung, M. P., Smith, D. A., Sundaram, S. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0725 · Cited by 149
Entinostat: a promising treatment option for patients with advanced breast cancer
Connolly, R. M., Rudek, M. A., & Piekarz, R. (2017) · Future Oncology · doi:10.2217/fon-2016-0526 · Cited by 148
Tufo, G., Jones, A. W. E., Wang, Z., Hamelin, J., Tajeddine, N., Esposti, D. D., Martel, C., Boursier, C., Gallerne, C., Migdal, C., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.193 · Cited by 148
Taeger, J., Moser, C., Hellerbrand, C., Mycielska, M. E., Glockzin, G., Schlitt, H. J., Geissler, E. K., Stoeltzing, O., & Lang, S. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0312 · Cited by 148
Fan, S., Wang, Y., Lu, J. L., Zheng, Y., Wu, D., Li, M., Hu, B., Zhang, Z.-F., Cheng, W. P., & Shan, Q. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089961 · Cited by 147
Genetics and Epigenetics of Human Retinoblastoma
Benavente, C. A., & Dyer, M. A. (2015) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040259 · Cited by 147
Claus, R., Lucas, D. M., Stilgenbauer, S., Ruppert, A. S., Yu, L., Zucknick, M., Mertens, D., Bühler, A., Oakes, C. C., Larson, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3090 · Cited by 147
RAS mutations in human cancers: Roles in precision medicine
Murugan, A. K., Grieco, M., & Tsuchida, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.007 · Cited by 146
Alternative therapies for Helicobacter pylori: probiotics and phytomedicine
Vítor, J. M. B., & Vale, F. F. (2011) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2011.00865.x · Cited by 146
The microbiome and hepatobiliary-pancreatic cancers
Mima, K., Nakagawa, S., Sawayama, H., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., Baba, Y., Yamashita, Y., Yoshida, N., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.001 · Cited by 142
The role of necroptosis in cancer: A double-edged sword?
Qin, X., Ma, D., Tan, Y., Wang, H., & Cai, Z. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.006 · Cited by 142
Shikonin Kills Glioma Cells through Necroptosis Mediated by RIP-1
Huang, C., Luo, Y., Zhao, J., Yang, F., Zhao, H., Fan, W., & Ge, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066326 · Cited by 141
HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment
Hartmann, S., Bhola, N. E., & Grandis, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0951 · Cited by 141
Eathiraj, S., Palma, R., Volckova, E., Hirschi, M., France, D. S., Ashwell, M. A., & Chan, T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213801 · Cited by 140
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Smolarz, B., Łukasiewicz, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052049 · Cited by 259
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Metadata
- Authors
- Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-05-20
- Volume
- 9
- Issue
- 1
- Pages
- 132-132
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4397293886
- Cited by
- 720
- References
- 1,264
- FWCI
- 109.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.